DB:1TB

Stock Analysis Report

Executive Summary

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of orphan protein-misfolding diseases.


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Orphazyme's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1TB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.7%

1TB

0.4%

DE Biotechs

-0.9%

DE Market


1 Year Return

n/a

1TB

10.0%

DE Biotechs

12.8%

DE Market

Return vs Industry: Insufficient data to determine how 1TB performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 1TB performed against the German Market.


Shareholder returns

1TBIndustryMarket
7 Day-2.7%0.4%-0.9%
30 Day21.8%-3.2%-0.4%
90 Day106.8%4.6%2.3%
1 Yearn/a10.3%10.0%16.3%12.8%
3 Yearn/a49.4%47.8%15.8%5.7%
5 Yearn/a13.9%11.5%19.7%3.3%

Price Volatility Vs. Market

How volatile is Orphazyme's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Orphazyme undervalued compared to its fair value and its price relative to the market?

10.8x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 1TB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 1TB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 1TB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 1TB is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1TB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1TB is overvalued based on its PB Ratio (10.8x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Orphazyme forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

4.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1TB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1TB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1TB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1TB's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 1TB's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1TB is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Orphazyme performed over the past 5 years?

-46.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1TB is currently unprofitable.

Growing Profit Margin: 1TB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1TB is unprofitable, and losses have increased over the past 5 years at a rate of -46% per year.

Accelerating Growth: Unable to compare 1TB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1TB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 1TB has a negative Return on Equity (-127.08%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Orphazyme's financial position?


Financial Position Analysis

Short Term Liabilities: 1TB's short term assets (DKK246.0M) exceed its short term liabilities (DKK44.4M).

Long Term Liabilities: 1TB's short term assets (DKK246.0M) exceed its long term liabilities (DKK9.7M).


Debt to Equity History and Analysis

Debt Level: 1TB is debt free.

Reducing Debt: 1TB had no debt 5 years ago.


Balance Sheet

Inventory Level: 1TB has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 1TB's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1TB has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 1TB has less than a year of cash runway if free cash flow continues to reduce at historical rates of -49.1% each year


Next Steps

Dividend

What is Orphazyme's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1TB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 1TB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1TB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1TB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1TB's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Kim Stratton (57yo)

0.3yrs

Tenure

Ms. Kim Stratton has been Chief Executive Officer of Orphazyme A/S since October 1, 2019. Ms. Stratton has been a Director at Vifor Pharma AG since May 08, 2019. Ms. Stratton was the Head of International  ...


Leadership Team

NamePositionTenureCompensationOwnership
Kim Stratton
Chief Executive Officer0.3yrsno datano data
Thomas Jensen
Co-Founder & Chief Scientific Officer0yrsno datano data
Anders Vadsholt
Chief Financial Officer3.2yrsno data0.47% DKK2.1m
Thomas Blaettler
Chief Medical Officer3.4yrsno datano data

3.2yrs

Average Tenure

51yo

Average Age

Experienced Management: 1TB's management team is considered experienced (3.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Martijn Kleijwegt
Independent Director3.1yrsno datano data
Rémi Droller
Independent Director5.1yrsno datano data
Georges Gemayel
Chairman5.5yrsno data0.32% DKK1.4m
Bo Hansen
Deputy Chairman3.1yrsno data0.30% DKK1.3m
Sten Verland
Independent Director10.1yrsno datano data
Anders Hedegaard
Independent Director2.3yrsno data0.023% DKK102.5k
Catherine Moukheibir
Independent Director3.1yrsno data0.030% DKK130.8k
Martin Bonde
Independent Director10.1yrsno data0.17% DKK754.1k

4.1yrs

Average Tenure

59.5yo

Average Age

Experienced Board: 1TB's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.9%.


Top Shareholders

Company Information

Orphazyme A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Orphazyme A/S
  • Ticker: 1TB
  • Exchange: DB
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ø3.312b
  • Listing Market Cap: ø443.156m
  • Shares outstanding: 27.04m
  • Website: https://www.orphazyme.com

Number of Employees


Location

  • Orphazyme A/S
  • Ole Maaløes Vej 3
  • Copenhagen
  • Capital Region of Denmark
  • 2200
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ORPHACPSE (OMX Nordic Exchange Copenhagen)YesCommon SharesDKDKKNov 2017
1TBDB (Deutsche Boerse AG)YesCommon SharesDEEURNov 2017
0CUMLSE (London Stock Exchange)YesCommon SharesGBDKKNov 2017
OZYM.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDNov 2017

Biography

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of orphan protein-misfolding diseases. It focuses on developing therapies for diseases caused by misfolding of proteins and lysosomal dysfunction. The company’s lead candidate, Arimoclomol, is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. It also focuses on developing a series of heat-shock protein amplifying drugs. The company was founded in 2009 and is headquartered in Copenhagen, Denmark. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 00:27
End of Day Share Price2020/02/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.